BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24-30. [PMID: 23792214 DOI: 10.1016/j.autrev.2013.06.002] [Cited by in Crossref: 201] [Cited by in F6Publishing: 213] [Article Influence: 22.3] [Reference Citation Analysis]
Number Citing Articles
1 Mishra N, Aden K, Blase JI, Baran N, Bordoni D, Tran F, Conrad C, Avalos D, Jaeckel C, Scherer M, Sørensen SB, Overgaard SH, Schulte B, Nikolaus S, Rey G, Gasparoni G, Lyons PA, Schultze JL, Walter J, Andersen V, Banos A, Bertsias G, Beyer M, Boumpas D, Finckh A, Franke A, Georges M, Gu W, Häsler R, Jawhara M, Kenyon A, Kratsch C, Krause R, Lauc G, Mangino M, Natoli G, Ostaszewski M, Pezer M, Raes J, Rahmouni S, Ramos-pamplona M, Reiz B, Rosati E, Sanoudou D, Satagopam V, Schneider R, Schulte-schrepping J, Sidiropoulos P, Smith KGC, Spector T, Vandeputte D, Vieira-silva S, Vojta A, Warnat-herresthal S, Zoldoš V, Dermitzakis ET, Schreiber S, Rosenstiel P; SYSCID Consortium. Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease. Genome Med 2022;14. [DOI: 10.1186/s13073-022-01112-z] [Reference Citation Analysis]
2 Bertani L. Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic Choices. JCM 2022;11:5267. [DOI: 10.3390/jcm11185267] [Reference Citation Analysis]
3 Rajabnia M, Hajimirzaei SM, Hatamnejad MR, Shahrokh S, Ghavami SB, Farmani M, Salarieh N, Ebrahimi N, Kazemifard N, Farahanie A, Sherkat G, Aghdaei HA. Obesity, a challenge in the management of inflammatory bowel diseases. Immunol Res. [DOI: 10.1007/s12026-022-09315-7] [Reference Citation Analysis]
4 Alharbi O, Aljebreen AM, Azzam NA, Almadi MA, Saeed M, Hajkhdermullaissa B, Asiri H, Almutairi A, Alruthia Y. Predictors of Anti-TNF Therapy Failure among Inflammatory Bowel Disease (IBD) Patients in Saudi Arabia: A Single-Center Study. JCM 2022;11:4157. [DOI: 10.3390/jcm11144157] [Reference Citation Analysis]
5 Sekhri S, Yarur AJ. Integrating new and emerging therapies into inflammatory bowel disease clinical practice. Curr Opin Gastroenterol 2022;38:328-36. [PMID: 35762692 DOI: 10.1097/MOG.0000000000000851] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pugliese D, Privitera G, Fiorani M, Parisio L, Calvez V, Papa A, Gasbarrini A, Armuzzi A. Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab. Therap Adv Gastroenterol 2022;15:17562848221102283. [PMID: 35721840 DOI: 10.1177/17562848221102283] [Reference Citation Analysis]
7 Liu L, Pu D, Wang D, Zhang M, Zhou C, Zhang Z, Feng B. Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis. Front Pharmacol 2022;13:905133. [DOI: 10.3389/fphar.2022.905133] [Reference Citation Analysis]
8 Nie K, Zhang C, Deng M, Luo W, Ma K, Xu J, Wu X, Yang Y, Wang X. A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn's Disease. Front Pharmacol 2022;13:870796. [PMID: 35517818 DOI: 10.3389/fphar.2022.870796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Azmanov H, Bayatra A, Ilan Y. Digital Analgesic Comprising a Second-Generation Digital Health System: Increasing Effectiveness by Optimizing the Dosing and Minimizing Side Effects. J Pain Res 2022;15:1051-60. [PMID: 35444460 DOI: 10.2147/JPR.S356319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Truta B. Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place. World J Gastroenterol 2022; 28(13): 1380-1383 [DOI: 10.3748/wjg.v28.i13.1380] [Reference Citation Analysis]
11 Pudipeddi A, Ko Y, Paramsothy S, Leong RW. Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Therap Adv Gastroenterol 2022;15:175628482210807. [DOI: 10.1177/17562848221080793] [Reference Citation Analysis]
12 Cheli S, Cozzi V, Cattaneo D, Norsa L, De Giacomo C, Clementi E, Moretti C. Fast clearance of anti-TNFα agents unrelated to antidrug antibodies: a case report. Eur J Clin Pharmacol 2022. [PMID: 35181819 DOI: 10.1007/s00228-022-03294-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Perrig K, Krupka N, Jordi SBU, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka SR, Juillerat P, Burri E, Zimmermann D, Maillard MH, Sulz MC, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therap Adv Gastroenterol 2022;15:175628482210741. [DOI: 10.1177/17562848221074188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Guo A, Ross C, Chande N, Gregor J, Ponich T, Khanna R, Sey M, Beaton M, Yan B, Kim RB, Wilson A. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists. Sci Rep 2022;12:1185. [PMID: 35075155 DOI: 10.1038/s41598-022-05208-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Ilan Y. Digital Medical Cannabis as Market Differentiator: Second-Generation Artificial Intelligence Systems to Improve Response. Front Med 2022;8:788777. [DOI: 10.3389/fmed.2021.788777] [Reference Citation Analysis]
16 Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med (Lausanne) 2021;8:765474. [PMID: 34988090 DOI: 10.3389/fmed.2021.765474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
17 Parrot L, Dong C, Carbonnel F, Meyer A. Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther 2021. [PMID: 34854100 DOI: 10.1111/apt.16714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Zhang CB, Tang J, Wang XD, Lyu KS, Huang M, Gao X. Multi-alleles predict primary non-response to infliximab therapy in Crohn's disease. Gastroenterol Rep (Oxf) 2021;9:427-34. [PMID: 34733528 DOI: 10.1093/gastro/goaa070] [Reference Citation Analysis]
19 Ishay Y, Potruch A, Schwartz A, Berg M, Jamil K, Agus S, Ilan Y. A digital health platform for assisting the diagnosis and monitoring of COVID-19 progression: An adjuvant approach for augmenting the antiviral response and mitigating the immune-mediated target organ damage. Biomed Pharmacother 2021;143:112228. [PMID: 34649354 DOI: 10.1016/j.biopha.2021.112228] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
20 Faelens R, Wang Z, Bouillon T, Declerck P, Ferrante M, Vermeire S, Dreesen E. Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis. Pharmaceutics 2021;13:1623. [PMID: 34683916 DOI: 10.3390/pharmaceutics13101623] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Song EM, Joo YH, Choe AR, Park Y, Tae CH, Hong JT, Moon CM, Kim SE, Jung HK, Shim KN, Cho KA, Jo I, Jung SA. Three-dimensional culture method enhances the therapeutic efficacies of tonsil-derived mesenchymal stem cells in murine chronic colitis model. Sci Rep 2021;11:19589. [PMID: 34599237 DOI: 10.1038/s41598-021-98711-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Papadopoulou D, Drakopoulos A, Lagarias P, Melagraki G, Kollias G, Afantitis A. In Silico Identification and Evaluation of Natural Products as Potential Tumor Necrosis Factor Function Inhibitors Using Advanced Enalos Asclepios KNIME Nodes. Int J Mol Sci 2021;22:10220. [PMID: 34638561 DOI: 10.3390/ijms221910220] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Miao X, Mao R, You Y, Zhou H, Qiu C, Li X, Chen Z, Ren J, Chen M, Wang P, Zheng R, Yin T. Intracolic ultrasound molecular imaging: a novel method for assessing colonic tumor necrosis factor-α expression in inflammatory bowel disease. Mol Med 2021;27:119. [PMID: 34556023 DOI: 10.1186/s10020-021-00379-z] [Reference Citation Analysis]
24 Malkov MI, Lee CT, Taylor CT. Regulation of the Hypoxia-Inducible Factor (HIF) by Pro-Inflammatory Cytokines. Cells 2021;10:2340. [PMID: 34571989 DOI: 10.3390/cells10092340] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
25 Bhattarai A, Kowalczyk W, Tran TN. A literature review on large intestinal hyperelastic constitutive modeling. Clin Biomech (Bristol, Avon) 2021;88:105445. [PMID: 34416632 DOI: 10.1016/j.clinbiomech.2021.105445] [Reference Citation Analysis]
26 Ye M, Wang C, Zhu J, Chen M, Wang S, Li M, Lu Y, Xiao P, Zhou M, Li X, Zhou R. An NF-κB-responsive long noncoding RNA, PINT, regulates TNF-α gene transcription by scaffolding p65 and EZH2. FASEB J 2021;35:e21667. [PMID: 34405442 DOI: 10.1096/fj.202002263R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Ding NS, McDonald JAK, Perdones-Montero A, Rees DN, Adegbola SO, Misra R, Hendy P, Penez L, Marchesi JR, Holmes E, Sarafian MH, Hart AL. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease. J Crohns Colitis 2020;14:1090-102. [PMID: 32119090 DOI: 10.1093/ecco-jcc/jjaa039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
28 Albshesh A, Taylor J, Savarino EV, Truyens M, Armuzzi A, Ribaldone DG, Shitrit AB, Fibelman M, Molander P, Liefferinckx C, Nancey S, Korani M, Rutka M, Barreiro-de Acosta M, Domislovic V, Suris G, Eriksson C, Alves C, Mpitouli A, di Jiang C, Tepeš K, Coletta M, Foteinogiannopoulou K, Gisbert JP, Amir-Barak H, Attauabi M, Seidelin J, Afif W, Marinelli C, Lobaton T, Pugliese D, Maharshak N, Cremer A, Limdi JK, Molnár T, Otero-Alvarin B, Krznaric Z, Magro F, Karmiris K, Raine T, Drobne D, Koutroubakis I, Chaparro M, Yanai H, Burisch J, Kopylov U. Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. J Clin Med 2021;10:2914. [PMID: 34209880 DOI: 10.3390/jcm10132914] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
29 Yang Y, Sheng Y, Wang J, Zhou X, Guan Q, Shen H, Li W, Ruan S. Aureusidin derivative CNQX inhibits chronic colitis inflammation and mucosal barrier damage by targeting myeloid differentiation 2 protein. J Cell Mol Med 2021;25:7257-69. [PMID: 34184406 DOI: 10.1111/jcmm.16755] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
30 Pinto Pais I, Espinheira MC, Trindade E, Amil Dias J. Optimizing Antitumor Necrosis Factor Treatment in Pediatric Inflammatory Bowel Disease With Therapeutic Drug Monitoring. J Pediatr Gastroenterol Nutr 2020;71:12-8. [PMID: 32142005 DOI: 10.1097/MPG.0000000000002704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Pękala A, Filip R, Aebisher D. Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study. J Clin Med 2021;10:2653. [PMID: 34208676 DOI: 10.3390/jcm10122653] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
32 Nguyen VQ, Eden K, Morrison HA, Sammons MB, Knight KK, Sorrentino S, Brock RM, Grider DJ, Allen IC, Sorrentino D. Noncanonical NF-κB Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated With Loss of Response to Anti-TNF Agents. Front Pharmacol 2021;12:655887. [PMID: 34177575 DOI: 10.3389/fphar.2021.655887] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
33 Ezirike Ladipo J, He Z, Chikwava K, Robbins K, Beri J, Molle-Rios Z. Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort. J Pediatr Gastroenterol Nutr 2021;73:352-7. [PMID: 34117193 DOI: 10.1097/MPG.0000000000003201] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
34 Zhang G, Ma L, Bai L, Li M, Guo T, Tian B, He Z, Fu Q. Inflammatory microenvironment-targeted nanotherapies. J Control Release 2021;334:114-26. [PMID: 33887284 DOI: 10.1016/j.jconrel.2021.04.018] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
35 Bertani L, Blandizzi C, Mumolo MG, Ceccarelli L, Albano E, Tapete G, Baiano Svizzero G, Zanzi F, Coppini F, de Bortoli N, Bellini M, Morganti R, Marchi S, Costa F. Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study. Clin Transl Gastroenterol 2020;11:e00174. [PMID: 32677804 DOI: 10.14309/ctg.0000000000000174] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
36 Santacana E, Rodríguez-Alonso L, Padullés A, Guardiola J, Bas J, Rodríguez-Moranta F, Serra K, Morandeira F, Colom H, Padullés N. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design. Ther Drug Monit 2020;42:102-10. [PMID: 31283556 DOI: 10.1097/FTD.0000000000000669] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
37 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Neri M, Guidi L, Gasbarrini A, Armuzzi A. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol 2021;14:17562848211006669. [PMID: 33995579 DOI: 10.1177/17562848211006669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Privitera G, Pugliese D, Onali S, Petito V, Scaldaferri F, Gasbarrini A, Danese S, Armuzzi A. Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmun Rev 2021;20:102832. [PMID: 33866066 DOI: 10.1016/j.autrev.2021.102832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
39 Casanova MJ, Chaparro M, Mínguez M, Ricart E, Taxonera C, García-López S, Guardiola J, López-San Román A, Iglesias E, Beltrán B, Sicilia B, Vera MI, Hinojosa J, Riestra S, Domènech E, Calvet X, Pérez-Calle JL, Martín-Arranz MD, Aldeguer X, Rivero M, Monfort D, Barrio J, Esteve M, Márquez L, Lorente R, García-Planella E, de Castro L, Bermejo F, Merino O, Rodríguez-Pérez A, Martínez-Montiel P, Van Domselaar M, Alcaín G, Domínguez-Cajal M, Muñoz C, Gomollón F, Fernández-Salazar L, García-Sepulcre MF, Rodríguez-Lago I, Gutiérrez A, Argüelles-Arias F, Rodriguez C, Rodríguez GE, Bujanda L, Llaó J, Varela P, Ramos L, Huguet JM, Almela P, Romero P, Navarro-Llavat M, Abad Á, Ramírez-de la Piscina P, Lucendo AJ, Sesé E, Madrigal RE, Charro M, García-Herola A, Pajares R, Khorrami S, Gisbert JP. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.Inflamm Bowel Dis. 2020;26:606-616. [PMID: 31504569 DOI: 10.1093/ibd/izz192] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
40 Forss A, Clements M, Myrelid P, Strid H, Söderman C, Wagner A, Andersson D, Hjelm F, Olén O, Ludvigsson JF, Halfvarson J; PROSE SWIBREG study group. Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up. Scand J Gastroenterol 2021;56:680-6. [PMID: 33794731 DOI: 10.1080/00365521.2021.1906946] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Gorenjak M, Zupin M, Jezernik G, Skok P, Potočnik U. Omics data integration identifies ELOVL7 and MMD gene regions as novel loci for adalimumab response in patients with Crohn's disease. Sci Rep 2021;11:5449. [PMID: 33750834 DOI: 10.1038/s41598-021-84909-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
43 Sardesai A, Dignass A, Quon P, Milev S, Cappelleri JC, Kisser A, Modesto I, Sharma PP. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. J Med Econ 2021;24:279-90. [PMID: 33502905 DOI: 10.1080/13696998.2021.1881323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. J Clin Med 2021;10:853. [PMID: 33669579 DOI: 10.3390/jcm10040853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
45 Reinisch W, Sandborn WJ, Danese S, Hébuterne X, Kłopocka M, Tarabar D, Vaňásek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hoy M, Goetsch M, Bliss C, Gupta C, Cataldi F, Vermeire S. Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. J Crohns Colitis 2021;15:938-49. [PMID: 33599720 DOI: 10.1093/ecco-jcc/jjab023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
46 Bravo F, Macpherson JA, Slack E, Patuto N, Cahenzli J, McCoy KD, Macpherson AJ, Juillerat P; SATICC (Sensitivity to Anti-TNF Inhibition in Crohn's disease and ulcerative Colitis) study group. Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up. Clin Transl Gastroenterol 2021;12:e00298. [PMID: 33735154 DOI: 10.14309/ctg.0000000000000298] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
47 Ilan Y. Improving Global Healthcare and Reducing Costs Using Second-Generation Artificial Intelligence-Based Digital Pills: A Market Disruptor. Int J Environ Res Public Health 2021;18:811. [PMID: 33477865 DOI: 10.3390/ijerph18020811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
48 Wu Y, Zhang L, Cao J, Wang H, Ye C, Zhuoma D, Yang P, Wang X. Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820976923. [PMID: 33425009 DOI: 10.1177/1756284820976923] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
49 Rundquist S, Sachs MC, Eriksson C, Olén O, Montgomery S, Halfvarson J; SWIBREG Study Group. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.Aliment Pharmacol Ther. 2021;53:471-483. [PMID: 33340426 DOI: 10.1111/apt.16193] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
50 Bethlehem L, van Echten-Deckert G. Ectoines as novel anti-inflammatory and tissue protective lead compounds with special focus on inflammatory bowel disease and lung inflammation. Pharmacol Res 2021;164:105389. [PMID: 33352226 DOI: 10.1016/j.phrs.2020.105389] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
51 Ventin-Holmberg R, Eberl A, Saqib S, Korpela K, Virtanen S, Sipponen T, Salonen A, Saavalainen P, Nissilä E. Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:1019-31. [PMID: 33300552 DOI: 10.1093/ecco-jcc/jjaa252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
52 Giráldez-Montero JM, Gonzalez-Lopez J, Campos-Toimil M, Lamas-Díaz MJ. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease: Limits and improvements. Br J Clin Pharmacol 2021;87:2216-27. [PMID: 33197071 DOI: 10.1111/bcp.14654] [Reference Citation Analysis]
53 Ilan Y. Second-Generation Digital Health Platforms: Placing the Patient at the Center and Focusing on Clinical Outcomes. Front Digit Health 2020;2:569178. [DOI: 10.3389/fdgth.2020.569178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
54 Battat R, Lukin D, Scherl EJ, Pola S, Kumar A, Okada L, Yang L, Jain A, Siegel CA. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1443-51. [PMID: 33252119 DOI: 10.1093/ibd/izaa313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
55 Popa IV, Burlacu A, Mihai C, Prelipcean CC. A Machine Learning Model Accurately Predicts Ulcerative Colitis Activity at One Year in Patients Treated with Anti-Tumour Necrosis Factor α Agents. Medicina (Kaunas) 2020;56:E628. [PMID: 33233514 DOI: 10.3390/medicina56110628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
56 Conrad A, Neven B, Mahlaoui N, Suarez F, Sokol H, Ruemmele FM, Rouzaud C, Moshous D, Lortholary O, Blanche S, Lanternier F. Infections in Patients with Chronic Granulomatous Disease Treated with Tumor Necrosis Factor Alpha Blockers for Inflammatory Complications. J Clin Immunol 2021;41:185-93. [PMID: 33150502 DOI: 10.1007/s10875-020-00901-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
57 Lima CCG, Queiroz NSF, Sobrado CW, Silva GLR, Nahas SC. CRITICAL ANALYSIS OF ANTI-TNF USE IN THE ERA OF NEW BIOLOGICAL AGENTS IN INFLAMMATORY BOWEL DISEASE. Arq Gastroenterol 2020;57:323-32. [PMID: 33027484 DOI: 10.1590/S0004-2803.202000000-59] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Liu CY, Tam SS, Huang Y, Dubé PE, Alhosh R, Girish N, Punit S, Nataneli S, Li F, Bender JM, Washington MK, Polk DB. TNF Receptor 1 Promotes Early-Life Immunity and Protects against Colitis in Mice. Cell Rep 2020;33:108275. [PMID: 33086075 DOI: 10.1016/j.celrep.2020.108275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Zeze K, Hirano A, Torisu T, Esaki M, Moriyama T, Umeno J, Kawasaki K, Fujioka S, Fuyuno Y, Matsuno Y, Kitazono T. Adding Thiopurine After Loss of Response to Infliximab Versus Early Combination in Treating Crohn's Disease: A Retrospective Study. Dig Dis Sci 2021;66:3124-31. [PMID: 32920717 DOI: 10.1007/s10620-020-06600-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Kessler A, Weksler-zangen S, Ilan Y. Role of the Immune System and the Circadian Rhythm in the Pathogenesis of Chronic Pancreatitis: Establishing a Personalized Signature for Improving the Effect of Immunotherapies for Chronic Pancreatitis. Pancreas 2020;49:1024-32. [DOI: 10.1097/mpa.0000000000001626] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
61 Penagini F, Cococcioni L, Pozzi E, Dilillo D, Rendo G, Mantegazza C, Zuccotti GV. Biological therapy in pediatric age. Pharmacol Res 2020;161:105120. [PMID: 32783974 DOI: 10.1016/j.phrs.2020.105120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
62 Brubaker DK, Kumar MP, Chiswick EL, Gregg C, Starchenko A, Vega PN, Southard-Smith AN, Simmons AJ, Scoville EA, Coburn LA, Wilson KT, Lau KS, Lauffenburger DA. An interspecies translation model implicates integrin signaling in infliximab-resistant inflammatory bowel disease. Sci Signal 2020;13:eaay3258. [PMID: 32753478 DOI: 10.1126/scisignal.aay3258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
63 Shannahan SE, Papamichael K, Cheifetz AS. Evidence Supporting High-Dose Use of Biologics in Clinical Practice. Curr Treat Options Gastro 2020;18:408-22. [DOI: 10.1007/s11938-020-00302-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Santacana Juncosa E, Rodríguez-Alonso L, Padullés Zamora A, Guardiola J, Rodríguez-Moranta F, Serra Nilsson K, Bas Minguet J, Morandeira Rego F, Colom Codina H, Padullés Zamora N. Bayes-based dosing of infliximab in inflammatory bowel diseases: Short-term efficacy. Br J Clin Pharmacol 2021;87:494-505. [PMID: 32495380 DOI: 10.1111/bcp.14410] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
65 Ilan Y. Overcoming Compensatory Mechanisms toward Chronic Drug Administration to Ensure Long-Term, Sustainable Beneficial Effects. Mol Ther Methods Clin Dev 2020;18:335-44. [PMID: 32671136 DOI: 10.1016/j.omtm.2020.06.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
66 Albshesh A, Ben-Horin S. Editorial: which biologic is next for ulcerative colitis patients who fail a subcutaneous anti-TNF? Aliment Pharmacol Ther 2020;51:1198-9. [PMID: 32424929 DOI: 10.1111/apt.15712] [Reference Citation Analysis]
67 Curciarello R, Sobande T, Jones S, Giuffrida P, Di Sabatino A, Docena GH, MacDonald TT, Kok K. Human Neutrophil Elastase Proteolytic Activity in Ulcerative Colitis Favors the Loss of Function of Therapeutic Monoclonal Antibodies. J Inflamm Res 2020;13:233-43. [PMID: 32547155 DOI: 10.2147/JIR.S234710] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
68 Guidi L, Pugliese D, Panici Tonucci T, Berrino A, Tolusso B, Basile M, Cantoro L, Balestrieri P, Civitelli F, Bertani L, Marzo M, Felice C, Gremese E, Costa F, Viola F, Cicala M, Kohn A, Gasbarrini A, Rapaccini GL, Ruggeri M, Armuzzi A. Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. J Crohns Colitis 2018;12:1079-88. [PMID: 29860436 DOI: 10.1093/ecco-jcc/jjy076] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 9.5] [Reference Citation Analysis]
69 Bertani L, Rossari F, Barberio B, Demarzo MG, Tapete G, Albano E, Baiano Svizzero G, Ceccarelli L, Mumolo MG, Brombin C, de Bortoli N, Bellini M, Marchi S, Bodini G, Savarino E, Costa F. Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. Inflamm Bowel Dis. 2020;26:1579-1587. [PMID: 32232392 DOI: 10.1093/ibd/izaa062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
70 Dovrolis N, Michalopoulos G, Theodoropoulos GE, Arvanitidis K, Kolios G, Sechi LA, Eliopoulos AG, Gazouli M. The Interplay between Mucosal Microbiota Composition and Host Gene-Expression is Linked with Infliximab Response in Inflammatory Bowel Diseases. Microorganisms 2020;8:E438. [PMID: 32244928 DOI: 10.3390/microorganisms8030438] [Cited by in Crossref: 15] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
71 Choi SY, Kang B, Choe YH. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease. Gut Liver 2019;13:541-8. [PMID: 30970435 DOI: 10.5009/gnl18129] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
72 Bauer CM, Younis A, Herfarth H, Barnes EL. Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease. Inflamm Bowel Dis 2020;26:e5. [PMID: 31750909 DOI: 10.1093/ibd/izz286] [Reference Citation Analysis]
73 Jung YJ, Tweedie D, Scerba MT, Greig NH. Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. Front Cell Dev Biol 2019;7:313. [PMID: 31867326 DOI: 10.3389/fcell.2019.00313] [Cited by in Crossref: 33] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
74 Lee KE, Jung SA, Joo YH, Song EM, Moon CM, Kim SE, Jo I. The efficacy of conditioned medium released by tonsil-derived mesenchymal stem cells in a chronic murine colitis model. PLoS One 2019;14:e0225739. [PMID: 31790467 DOI: 10.1371/journal.pone.0225739] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
75 Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020;14:694-709. [DOI: 10.1093/ecco-jcc/jjz195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 62] [Article Influence: 12.7] [Reference Citation Analysis]
76 Khoury T, Ilan Y. Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies. Front Immunol 2019;10:2726. [PMID: 31824506 DOI: 10.3389/fimmu.2019.02726] [Cited by in Crossref: 16] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
77 Liu H, Dasgupta S, Fu Y, Bailey B, Roy C, Lightcap E, Faustin B. Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBD. BMC Immunol. 2019;20:42. [PMID: 31718550 DOI: 10.1186/s12865-019-0322-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
78 Lopetuso LR, Gasbarrini A. Fighting the Hype for Predictors of Efficacy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2020;26:764-5. [DOI: 10.1093/ibd/izz274] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Bertani L, Antonioli L, Fornai M, Tapete G, Baiano Svizzero G, Marchi S, Blandizzi C, Costa F. Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. Minerva Gastroenterol Dietol 2019;65:298-308. [PMID: 31646851 DOI: 10.23736/S1121-421X.19.02621-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
80 Schmitt H, Neufert C, Neurath MF, Atreya R. Resolution of Crohn's disease. Semin Immunopathol 2019;41:737-46. [PMID: 31552470 DOI: 10.1007/s00281-019-00756-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
81 Engel T, Yung DE, Ma C, Pariente B, Wils P, Eliakim R, Ungar B, Ben-horin S, Kopylov U. Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence. Digestive and Liver Disease 2019;51:1232-40. [DOI: 10.1016/j.dld.2019.05.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
82 Ungar B, Ben-shatach Z, Ben-haim G, Yavzori M, Picard O, Fudim E, Kopylov U, Veyrard P, Del Tedesco É, Paul S, Eliakim R, Ben-horin S, Roblin X. Infliximab therapy intensification upon loss of response: Is there an optimal trough level? Digestive and Liver Disease 2019;51:1106-11. [DOI: 10.1016/j.dld.2019.02.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
83 Eftychi C, Schwarzer R, Vlantis K, Wachsmuth L, Basic M, Wagle P, Neurath MF, Becker C, Bleich A, Pasparakis M. Temporally Distinct Functions of the Cytokines IL-12 and IL-23 Drive Chronic Colon Inflammation in Response to Intestinal Barrier Impairment. Immunity 2019;51:367-380.e4. [PMID: 31350179 DOI: 10.1016/j.immuni.2019.06.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 41] [Article Influence: 8.7] [Reference Citation Analysis]
84 Strik AS, Berends SE, Löwenberg M. Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward? Expert Rev Clin Pharmacol 2019;12:885-91. [PMID: 31305158 DOI: 10.1080/17512433.2019.1642745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
85 Schultheiss JPD, Brand EC, Lamers E, van den Berg WCM, van Schaik FDM, Oldenburg B, Fidder HH. Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects. Aliment Pharmacol Ther 2019;50:386-96. [PMID: 31310690 DOI: 10.1111/apt.15380] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
86 Song JH, Hong SN, Lee JE, Kim K, Kim TJ, Kim ER, Chang DK, Kim YH. C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease. Scand J Gastroenterol 2019;54:876-85. [PMID: 31303093 DOI: 10.1080/00365521.2019.1638962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Meyer C, Bowers A, Heavener TE, Checketts JX, Vassar M. From clinical practice guideline development to trial registration: A systematic investigation of research pipeline for inflammatory bowel disease. Indian J Gastroenterol 2019;38:247-62. [PMID: 31270778 DOI: 10.1007/s12664-019-00965-4] [Reference Citation Analysis]
88 Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?Curr Opin Gastroenterol. 2019;35:302-310. [PMID: 30973355 DOI: 10.1097/MOG.0000000000000536] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
89 Franca R, Curci D, Lucafò M, Decorti G, Stocco G. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. Expert Opin Drug Metab Toxicol 2019;15:527-39. [PMID: 31177858 DOI: 10.1080/17425255.2019.1630378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
90 Jang EJ, Ha JE, Im SG, Kim MG, Sohn HS. A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNFα Therapy for Inflammatory Bowel Disease. Clin Drug Investig 2019;39:625-30. [DOI: 10.1007/s40261-019-00784-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
91 Battat R, Dulai PS, Jairath V, Vande Casteele N. A product review of vedolizumab in inflammatory bowel disease. Hum Vaccin Immunother 2019;15:2482-90. [PMID: 30897022 DOI: 10.1080/21645515.2019.1591139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
92 Ince MN, Elliott DE. Effective Use of the Laboratory in the Management of Patients with Inflammatory Bowel Diseases. Gastroenterol Clin North Am 2019;48:237-58. [PMID: 31046973 DOI: 10.1016/j.gtc.2019.02.006] [Reference Citation Analysis]
93 Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, Hirschmann S, Hildner K, Waldner MJ, Mudter J, Hartmann A, Grützmann R, Neufert C, Münster T, Neurath MF, Atreya R. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease. Gut 2019;68:814-28. [PMID: 29848778 DOI: 10.1136/gutjnl-2017-315671] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 25.3] [Reference Citation Analysis]
94 Jiang HY, Shi YD, Zhang X, Pan LY, Xie YR, Jiang CM, Deng M, Ruan B. Human papillomavirus vaccination and the risk of autoimmune disorders: A systematic review and meta-analysis. Vaccine 2019;37:3031-9. [PMID: 31036452 DOI: 10.1016/j.vaccine.2019.04.049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
95 He Y, Yu H, Ge Y, Li X, Jiang M, Liu Y, Li X, Wang Y, Guo M, Qin X, Wang X. Bacterial β-glucuronidase alleviates dextran sulfate sodium-induced colitis in mice: A possible crucial new diagnostic and therapeutic target for inflammatory bowel disease. Biochem Biophys Res Commun 2019;513:426-33. [PMID: 30967260 DOI: 10.1016/j.bbrc.2019.03.196] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
96 Gaujoux R, Starosvetsky E, Maimon N, Vallania F, Bar-Yoseph H, Pressman S, Weisshof R, Goren I, Rabinowitz K, Waterman M, Yanai H, Dotan I, Sabo E, Chowers Y, Khatri P, Shen-Orr SS; Israeli IBD research Network (IIRN). Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD. Gut 2019;68:604-14. [PMID: 29618496 DOI: 10.1136/gutjnl-2017-315494] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 33.3] [Reference Citation Analysis]
97 Battat R, Ma C, Jairath V, Khanna R, Feagan BG. Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis. Drug Saf 2019;42:617-32. [DOI: 10.1007/s40264-018-00783-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
98 Lamb CA, O'Byrne S, Keir ME, Butcher EC. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease. J Crohns Colitis 2018;12:S653-68. [PMID: 29767705 DOI: 10.1093/ecco-jcc/jjy060] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
99 Zhang H, Xu CN, Mine Y. Effects of a synthetic di‐phosphoserine peptide (SS‐2) on gene expression profiling against TNF‐α induced inflammation. Int J Food Sci Technol 2019;54:2010-20. [DOI: 10.1111/ijfs.14077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
100 Saad RE, Shobar R, Mutlu EA. Collagenous colitis development occurs after long standing mucosal healing in IBD with TNF-α inhibitors, and could be due to exaggerated healing response from excess TNF-α inhibition. Med Hypotheses 2019;123:90-4. [PMID: 30696605 DOI: 10.1016/j.mehy.2019.01.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
101 Ilan Y. Immune rebalancing by oral immunotherapy: A novel method for getting the immune system back on track. J Leukoc Biol 2019;105:463-72. [PMID: 30476347 DOI: 10.1002/JLB.5RU0718-276RR] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
102 Aoki R, Aoki-Yoshida A, Suzuki C, Takayama Y. Indole-3-Pyruvic Acid, an Aryl Hydrocarbon Receptor Activator, Suppresses Experimental Colitis in Mice. J Immunol 2018;201:3683-93. [PMID: 30429284 DOI: 10.4049/jimmunol.1701734] [Cited by in Crossref: 34] [Cited by in F6Publishing: 50] [Article Influence: 8.5] [Reference Citation Analysis]
103 Stevens TW, Matheeuwsen M, Lönnkvist MH, Parker CE, Wildenberg ME, Gecse KB, D’haens GR. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. Aliment Pharmacol Ther 2018;48:1213-31. [DOI: 10.1111/apt.15033] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
104 Rundquist S, Eriksson C, Nilsson L, Angelison L, Jäghult S, Björk J, Grip O, Hjortswang H, Strid H, Karlén P, Montgomery S, Halfvarson J. Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scandinavian Journal of Gastroenterology 2018;53:1257-63. [DOI: 10.1080/00365521.2018.1519597] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
105 Dragoni G, Le Grazie M, Orlandini B, Rogai F. Golimumab in inflammatory bowel diseases: present and future scenarios. Clin J Gastroenterol 2019;12:1-9. [DOI: 10.1007/s12328-018-0906-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
106 Engel T, Ungar B, Yung DE, Ben-Horin S, Eliakim R, Kopylov U. Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. J Crohns Colitis. 2018;12:245-257. [PMID: 29077833 DOI: 10.1093/ecco-jcc/jjx143] [Cited by in Crossref: 74] [Cited by in F6Publishing: 80] [Article Influence: 18.5] [Reference Citation Analysis]
107 Pagnini C, Siakavellas SI, Bamias G. Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients. Gastroenterol Res Pract 2018;2018:6317057. [PMID: 30116266 DOI: 10.1155/2018/6317057] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
108 Rufino MN, Aleixo GFP, Trombine-Batista IE, Giuffrida R, Keller R, Bremer-Neto H. Systematic review and meta-analysis of preclinical trials demonstrate robust beneficial effects of prebiotics in induced inflammatory bowel disease. J Nutr Biochem. 2018;62:1-8. [PMID: 30053633 DOI: 10.1016/j.jnutbio.2018.05.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
109 Feng T, Chen B, Li L, Huang S, Ben-Horin S, Qiu Y, Feng R, Li M, Mao R, He Y, Zeng Z, Zhang S, Chen M. Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease. Inflamm Bowel Dis 2017;23:1817-24. [PMID: 28644181 DOI: 10.1097/MIB.0000000000001172] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
110 Papamichael K, Vande Casteele N, Ferrante M, Gils A, Cheifetz AS. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflamm Bowel Dis. 2017;23:1510-1515. [PMID: 28816757 DOI: 10.1097/mib.0000000000001231] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 12.0] [Reference Citation Analysis]
111 Steeland S, Libert C, Vandenbroucke RE. A New Venue of TNF Targeting. Int J Mol Sci 2018;19:E1442. [PMID: 29751683 DOI: 10.3390/ijms19051442] [Cited by in Crossref: 52] [Cited by in F6Publishing: 61] [Article Influence: 13.0] [Reference Citation Analysis]
112 Bodini G, Giannini EG, Savarino V, Del Nero L, Lo Pumo S, Brunacci M, De Bortoli N, Jain A, Tolone S, Savarino E. Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. Digestive and Liver Disease 2018;50:452-6. [DOI: 10.1016/j.dld.2017.11.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
113 Martin DA, Smyth JA, Liu Z, Bolling BW. Aronia berry (Aronia mitschurinii ‘Viking’) inhibits colitis in mice and inhibits T cell tumour necrosis factor-α secretion. Journal of Functional Foods 2018;44:48-57. [DOI: 10.1016/j.jff.2018.02.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
114 Buhl S, Steenholdt C, Rasmussen M, Borghede MK, Brynskov J, Thomsen OØ, Ainsworth MA. Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1210-7. [PMID: 28445244 DOI: 10.1097/MIB.0000000000001117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
115 Bonaz B. Is-there a place for vagus nerve stimulation in inflammatory bowel diseases? Bioelectron Med 2018;4:4. [PMID: 32232080 DOI: 10.1186/s42234-018-0004-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
116 Kim YS. [How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?]. Korean J Gastroenterol 2018;71:74-80. [PMID: 29471604 DOI: 10.4166/kjg.2018.71.2.74] [Reference Citation Analysis]
117 Lee KM. [Monitoring Disease Activity: How and When?]. Korean J Gastroenterol 2018;71:69-73. [PMID: 29471603 DOI: 10.4166/kjg.2018.71.2.69] [Reference Citation Analysis]
118 Lee SD, Rubin DT, Sandborn WJ, Randall C, Younes Z, Schreiber S, Schwartz DA, Burakoff R, Binion D, Dassopoulos T, Arsenescu R, Gutierrez A, Scherl E, Kayhan C, Hasan I, Kosutic G, Spearman M, Sen D, Coarse J, Hanauer S. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis 2016;22:1870-80. [PMID: 27400222 DOI: 10.1097/MIB.0000000000000805] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
119 Soubières AA, Poullis A. Emerging Biomarkers for the Diagnosis and Monitoring of Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016;22:2016-2022. [PMID: 27416044 DOI: 10.1097/mib.0000000000000836] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
120 Santacana E, Rodríguez-alonso L, Padullés A, Guardiola J, Rodríguez-moranta F, Serra K, Bas J, Morandeira, Biology F, Colom H, Padullés N. External Evaluation of Population Pharmacokinetic Models of Infliximab in Patients With Inflammatory Bowel Disease. Therapeutic Drug Monitoring 2018;40:120-9. [DOI: 10.1097/ftd.0000000000000476] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
121 Luther J, Gala M, Patel SJ, Dave M, Borren N, Xavier RJ, Ananthakrishnan AN. Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways. Dig Dis Sci 2018;63:738-45. [PMID: 29372477 DOI: 10.1007/s10620-018-4932-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
122 Gendelman O, Weitzman D, Rosenberg V, Shalev V, Chodick G, Amital H. Characterization of adherence and persistence profile in a real-life population of patients treated with adalimumab. Br J Clin Pharmacol 2018;84:786-95. [PMID: 29272556 DOI: 10.1111/bcp.13494] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
123 Hofmekler T, Bertha M, McCracken C, Martineau B, McKinnon E, Schoen BT, McElhanon BO, Tenjarla G, Kugathasan S, Sauer CG. Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2017;64:580-5. [PMID: 28079601 DOI: 10.1097/MPG.0000000000001302] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
124 Corica D, Romano C. Biological Therapy in Pediatric Inflammatory Bowel Disease: A Systematic Review. J Clin Gastroenterol. 2017;51:100-110. [PMID: 27636407 DOI: 10.1097/mcg.0000000000000696] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
125 Murray CD. Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine. Aliment Pharmacol Ther 2018;47:141-2. [PMID: 29226412 DOI: 10.1111/apt.14392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
126 Beattie DT, Pulido-Rios MT, Shen F, Ho M, Situ E, Tsuruda PR, Brassil P, Kleinschek M, Hegde S. Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy. J Inflamm (Lond) 2017;14:28. [PMID: 29225517 DOI: 10.1186/s12950-017-0175-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
127 Armuzzi A, Felice C, Lubrano E, Cantini F, Castiglione F, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Marchesoni A, Vecchi M, Olivieri I. Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. Digestive and Liver Disease 2017;49:1298-305. [DOI: 10.1016/j.dld.2017.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
128 Goettel JA, Gandhi R, Kenison JE, Yeste A, Murugaiyan G, Sambanthamoorthy S, Griffith AE, Patel B, Shouval DS, Weiner HL, Snapper SB, Quintana FJ. AHR Activation Is Protective against Colitis Driven by T Cells in Humanized Mice. Cell Rep 2016;17:1318-29. [PMID: 27783946 DOI: 10.1016/j.celrep.2016.09.082] [Cited by in Crossref: 90] [Cited by in F6Publishing: 98] [Article Influence: 18.0] [Reference Citation Analysis]
129 Fay S, Ungar B, Paul S, Levartovsky A, Yavzori M, Fudim E, Picard O, Eliakim R, Ben-horin S, Roblin X, Kopylov U. The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohnʼs Disease Treated with Tumor Necrosis Factor Inhibitors: . Inflammatory Bowel Diseases 2017;23:1924-9. [DOI: 10.1097/mib.0000000000001220] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
130 Eun CS. Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients? Gut Liver 2017;11:3-4. [PMID: 28053295 DOI: 10.5009/gnl16574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
131 Loftus EV, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis. 2017;11:400-411. [PMID: 27683800 DOI: 10.1093/ecco-jcc/jjw177] [Cited by in Crossref: 24] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
132 Martineau C, Flourié B, Wils P, Vaysse T, Altwegg R, Buisson A, Amiot A, Pineton de Chambrun G, Abitbol V, Fumery M, Hébuterne X, Viennot S, Laharie D, Beaugerie L, Nancey S, Sokol H; the Goli-Crohn Study Group. Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. Aliment Pharmacol Ther 2017;46:1077-84. [DOI: 10.1111/apt.14371] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
133 Lopetuso LR, Gerardi V, Papa V, Scaldaferri F, Rapaccini GL, Gasbarrini A, Papa A. Can We Predict the Efficacy of Anti-TNF-α Agents? Int J Mol Sci 2017;18:E1973. [PMID: 28906475 DOI: 10.3390/ijms18091973] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 8.6] [Reference Citation Analysis]
134 Wong U, Cross RK. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures. Expert Opin Drug Metab Toxicol 2017;13:1039-46. [PMID: 28876147 DOI: 10.1080/17425255.2017.1377180] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
135 Ding NS, Malietzis G, Lung PFC, Penez L, Yip WM, Gabe S, Jenkins JT, Hart A. The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm. Aliment Pharmacol Ther 2017;46:883-91. [PMID: 28881017 DOI: 10.1111/apt.14293] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
136 Navas-lópez V, Ramos-rueda N, Pujol-muncunill G, Martín de Carpi J. Metotrexato en la enfermedad inflamatoria intestinal pediátrica. Enfermedad Inflamatoria Intestinal al Día 2017;16:127-37. [DOI: 10.1016/j.eii.2016.12.003] [Reference Citation Analysis]
137 Liang J, Liang J, Hao H, Lin H, Wang P, Wu Y, Jiang X, Fu C, Li Q, Ding P, Liu H, Xiong Q, Lai X, Zhou L, Chan S, Hou S. The Extracts of Morinda officinalis and Its Hairy Roots Attenuate Dextran Sodium Sulfate-Induced Chronic Ulcerative Colitis in Mice by Regulating Inflammation and Lymphocyte Apoptosis. Front Immunol 2017;8:905. [PMID: 28824631 DOI: 10.3389/fimmu.2017.00905] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
138 Feagins LA, Waljee A, Hou JK, Gu P, Kanjo S, Rudrapatna V, Cipher DJ, Govani S, Gaidos J. Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2017;23:1434-9. [DOI: 10.1097/mib.0000000000001145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
139 Liefferinckx C, Minsart C, Toubeau J, Cremer A, Amininejad L, Quertinmont E, Devière J, Gils A, van Gossum A, Franchimont D. Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance: . Inflammatory Bowel Diseases 2017;23:1371-81. [DOI: 10.1097/mib.0000000000001120] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
140 Schneider A, Hossain I, VanderMolen J, Nicol K. Comparison of remicade to curcumin for the treatment of Crohn's disease: A systematic review. Complement Ther Med 2017;33:32-8. [PMID: 28735823 DOI: 10.1016/j.ctim.2017.06.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
141 Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018;29:13-18. [PMID: 28521565 DOI: 10.1080/09546634.2017.1329511] [Cited by in Crossref: 78] [Cited by in F6Publishing: 86] [Article Influence: 15.6] [Reference Citation Analysis]
142 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. [Second Korean Guidelines for the Management of Crohn's Disease]. Korean J Gastroenterol 2017;69:29-54. [PMID: 28135790 DOI: 10.4166/kjg.2017.69.1.29] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
143 Higa LH, Jerez HE, de Farias MA, Portugal RV, Romero EL, Morilla MJ. Ultra-small solid archaeolipid nanoparticles for active targeting to macrophages of the inflamed mucosa. Nanomedicine 2017;12:1165-75. [DOI: 10.2217/nnm-2016-0437] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
144 Pulkoski-Gross MJ, Uys JD, Orr-Gandy KA, Coant N, Bialkowska AB, Szulc ZM, Bai A, Bielawska A, Townsend DM, Hannun YA, Obeid LM, Snider AJ. Novel sphingosine kinase-1 inhibitor, LCL351, reduces immune responses in murine DSS-induced colitis. Prostaglandins Other Lipid Mediat 2017;130:47-56. [PMID: 28377281 DOI: 10.1016/j.prostaglandins.2017.03.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
145 Szymanska E, Dadalski M, Grajkowska W, Szymanska S, Pronicki M, Kierkus J. Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn's disease. Prz Gastroenterol 2017;12:44-8. [PMID: 28337236 DOI: 10.5114/pg.2016.64746] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
146 Novak G, Hindryckx P, Khanna R, Jairath V, Feagan BG. The safety of vedolizumab for the treatment of ulcerative colitis.Expert Opin Drug Saf. 2017;16:501-507. [PMID: 28276855 DOI: 10.1080/14740338.2017.1300251] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
147 Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI. IBD immunopathogenesis: A comprehensive review of inflammatory molecules. Autoimmun Rev. 2017;16:416-426. [PMID: 28212924 DOI: 10.1016/j.autrev.2017.02.013] [Cited by in Crossref: 121] [Cited by in F6Publishing: 150] [Article Influence: 24.2] [Reference Citation Analysis]
148 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of Crohn's disease. Intest Res 2017;15:38-67. [PMID: 28239314 DOI: 10.5217/ir.2017.15.1.38] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
149 Nishida Y, Hosomi S, Yamagami H, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Tanigawa T, Shiba M, Watanabe K, Watanabe T, Tominaga K, Fujiwara Y. Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis. PLoS One. 2017;12:e0169845. [PMID: 28076386 DOI: 10.1371/journal.pone.0169845] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
150 Hirose M, Kasprick A, Beltsiou F, Dieckhoff Schulze K, Schulze FS, Samavedam UK, Hundt JE, Pas HH, Jonkman MF, Schmidt E, Kalies K, Zillikens D, Ludwig RJ, Bieber K. Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment. Mol Med 2017;22:918-26. [PMID: 27999842 DOI: 10.2119/molmed.2015.00206] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
151 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 830] [Cited by in F6Publishing: 1116] [Article Influence: 138.3] [Reference Citation Analysis]
152 Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017;15:229-239.e5. [PMID: 27639327 DOI: 10.1016/j.cgh.2016.08.044] [Cited by in Crossref: 114] [Cited by in F6Publishing: 104] [Article Influence: 19.0] [Reference Citation Analysis]
153 Slevin SM, Egan LJ. New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:2909-2920. [PMID: 26348448 DOI: 10.1097/mib.0000000000000533] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
154 Marini JC, Sendecki J, Cornillie F, Popp JW Jr, Black S, Blank M, Gils A, Van Stappen T, Hamann D, Rispens T, Thérien L, Chun K, Shankar G. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®. AAPS J 2017;19:161-71. [PMID: 27600137 DOI: 10.1208/s12248-016-9981-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
155 Eder P, Korybalska K, Lykowska-Szuber L, Krela-Kazmierczak I, Stawczyk-Eder K, Klimczak K, Szymczak A, Linke K, Witowski J. Association of serum VEGF with clinical response to anti-TNFα therapy for Crohn's disease. Cytokine 2015;76:288-93. [PMID: 26481259 DOI: 10.1016/j.cyto.2015.09.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
156 Selmi C. Autoimmunity in 2014. Clin Rev Allergy Immunol 2015;49:93-9. [PMID: 26335699 DOI: 10.1007/s12016-015-8504-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
157 Kedia S, Ahuja V, Makharia GK. Golimumab for moderately to severely active ulcerative colitis. Expert Rev Clin Pharmacol 2016;9:1273-82. [PMID: 27498886 DOI: 10.1080/17512433.2016.1221759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
158 Luissint AC, Parkos CA, Nusrat A. Inflammation and the Intestinal Barrier: Leukocyte-Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal Repair. Gastroenterology 2016;151:616-32. [PMID: 27436072 DOI: 10.1053/j.gastro.2016.07.008] [Cited by in Crossref: 177] [Cited by in F6Publishing: 229] [Article Influence: 29.5] [Reference Citation Analysis]
159 Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther. 2016;16:1277-1290. [PMID: 27329436 DOI: 10.1080/14712598.2016.1203897] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
160 Haep L, Britzen-Laurent N, Weber TG, Naschberger E, Schaefer A, Kremmer E, Foersch S, Vieth M, Scheuer W, Wirtz S. Interferon Gamma Counteracts the Angiogenic Switch and Induces Vascular Permeability in Dextran Sulfate Sodium Colitis in Mice. Inflamm Bowel Dis. 2015;21:2360-2371. [PMID: 26164664 DOI: 10.1097/mib.0000000000000490] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
161 Magis Q, Jullien D, Gaudy-marqueste C, Baumstark K, Viguier M, Bachelez H, Guibal F, Delaporte E, Karimova E, Montaudié H, Boye T, Aubin F, Beylot-barry M, Richard M; the “Groupe de Recherche sur le Psoriasis de la Société Française”. Predictors of long-term drug survival for infliximab in psoriasis. J Eur Acad Dermatol Venereol 2017;31:96-101. [DOI: 10.1111/jdv.13747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
162 Sieczkowska J, Jarzębicka D, Meglicka M, Oracz G, Kierkus J. Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases. Therap Adv Gastroenterol 2016;9:729-35. [PMID: 27582886 DOI: 10.1177/1756283X16650155] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
163 Ungar B, Mazor Y, Weisshof R, Yanai H, Ron Y, Goren I, Waizbard A, Yavzori M, Fudim E, Picard O, Loebstein R, Kopylov U, Dotan I, Chowers Y, Eliakim R, Ben-horin S. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Aliment Pharmacol Ther 2016;43:1293-9. [DOI: 10.1111/apt.13631] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 9.5] [Reference Citation Analysis]
164 Perricone C, Versini M, Ben-ami D, Gertel S, Watad A, Segel MJ, Ceccarelli F, Conti F, Cantarini L, Bogdanos DP, Antonelli A, Amital H, Valesini G, Shoenfeld Y. Smoke and autoimmunity: The fire behind the disease. Autoimmunity Reviews 2016;15:354-74. [DOI: 10.1016/j.autrev.2016.01.001] [Cited by in Crossref: 97] [Cited by in F6Publishing: 95] [Article Influence: 16.2] [Reference Citation Analysis]
165 Kopylov U, Seidman E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol 2016;9:513-26. [PMID: 27366220 DOI: 10.1177/1756283X16638833] [Cited by in Crossref: 33] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
166 Papamichael K, Rivals-Lerebours O, Billiet T, Vande Casteele N, Gils A, Ferrante M, Van Assche G, Rutgeerts PJ, Mantzaris GJ, Peyrin-Biroulet L, Vermeire S. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. J Crohns Colitis. 2016;10:1015-1023. [PMID: 27022161 DOI: 10.1093/ecco-jcc/jjw067] [Cited by in Crossref: 36] [Cited by in F6Publishing: 47] [Article Influence: 6.0] [Reference Citation Analysis]
167 Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016;7:289-300. [PMID: 28839870 DOI: 10.1136/flgastro-2016-100685] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 11.3] [Reference Citation Analysis]
168 Furfaro F, Fiorino G, Allocca M, Gilardi D, Danese S. Emerging therapeutic targets and strategies in Crohn's disease. Expert Rev Gastroenterol Hepatol 2016;10:735-44. [PMID: 26766496 DOI: 10.1586/17474124.2016.1142372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
169 Szymanska E, Dadalski M, Szymanska S, Grajkowska W, Pronicki M, Kierkus J. The impact of induction therapy with three doses of infliximab on deep histological healing in paediatric patients with active Crohn's disease. Prz Gastroenterol 2016;11:176-80. [PMID: 27713779 DOI: 10.5114/pg.2016.57753] [Reference Citation Analysis]
170 Pugliese D, Felice C, Landi R, Papa A, Guidi L, Armuzzi A. Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug Healthc Patient Saf. 2016;8:1-7. [PMID: 26893582 DOI: 10.2147/dhps.s62649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
171 Vedak P, Kroshinsky D, St John J, Xavier RJ, Yajnik V, Ananthakrishnan AN. Genetic basis of TNF-α antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis. Aliment Pharmacol Ther 2016;43:697-704. [PMID: 26806281 DOI: 10.1111/apt.13542] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
172 Berns M, Hommes DW. Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opinion on Investigational Drugs 2016;25:129-43. [DOI: 10.1517/13543784.2016.1126247] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
173 Roda G, Jharap B, Neeraj N, Colombel JF. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016;7:e135. [PMID: 26741065 DOI: 10.1038/ctg.2015.63] [Cited by in Crossref: 236] [Cited by in F6Publishing: 283] [Article Influence: 39.3] [Reference Citation Analysis]
174 Amiot A, Stefanescu C, Bouhnik Y. Editorial: what can be done when infliximab stops working in ulcerative colitis? Authors' reply. Aliment Pharmacol Ther 2016;43:165. [PMID: 26638931 DOI: 10.1111/apt.13439] [Reference Citation Analysis]
175 Severs M, van Erp SJ, van der Valk ME, Mangen MJ, Fidder HH, van der Have M, van Bodegraven AA, de Jong DJ, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, van de Meeberg PC, Mahmmod N, Ponsioen CY, Bolwerk C, Vermeijden JR, Pierik MJ, Siersema PD, Leenders M, van der Meulen-de Jong AE, Dijkstra G, Oldenburg B; Dutch Initiative on Crohn and Colitis. Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis 2016;10:455-61. [PMID: 26721937 DOI: 10.1093/ecco-jcc/jjv238] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
176 Stallmach A, Schmidt C, Teich N. Vedolizumab for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2015;10:165-75. [DOI: 10.1586/17474124.2016.1123618] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
177 Oude Munnink TH, Henstra MJ, Segerink LI, Movig KL, Brummelhuis-Visser P. Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology. Clin Pharmacol Ther 2016;99:419-31. [PMID: 26265133 DOI: 10.1002/cpt.211] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
178 Massafra V, Ijssennagger N, Plantinga M, Milona A, Ramos Pittol JM, Boes M, van Mil SW. Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis. Biochim Biophys Acta 2016;1862:166-73. [PMID: 26554605 DOI: 10.1016/j.bbadis.2015.11.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
179 Eder P, Łykowska-Szuber L, Katulska K, Stawczyk-Eder K, Krela-Kaźmierczak I, Klimczak K, Szymczak A, Stajgis M, Linke K. Intestinal healing after anti-TNF induction therapy predicts long-term response to one-year treatment in patients with ileocolonic Crohn's disease naive to anti-TNF agents. Prz Gastroenterol 2016;11:187-93. [PMID: 27713781 DOI: 10.5114/pg.2015.55185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
180 Sartini A, Di Girolamo M, Bertani A, Villa E. “Blindly” ADA Dose Escalation to 80 mg Weekly in Crohnʼs Disease Patients with LOR: Is It Cost Effective or Not? Inflammatory Bowel Diseases 2015;21:E27-8. [DOI: 10.1097/mib.0000000000000604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
181 Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Aliment Pharmacol Ther 2016;43:30-51. [PMID: 26515897 DOI: 10.1111/apt.13445] [Cited by in Crossref: 182] [Cited by in F6Publishing: 169] [Article Influence: 26.0] [Reference Citation Analysis]
182 Gómez-Gómez GJ, Masedo &, Yela C, Martínez-Montiel MDP, Casís B. Current stage in inflammatory bowel disease: What is next? World J Gastroenterol 2015; 21(40): 11282-11303 [PMID: 26525013 DOI: 10.3748/wjg.v21.i40.11282] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
183 Martínez-Montiel MP, Casis-Herce B, Gómez-Gómez GJ, Masedo-González A, Yela-San Bernardino C, Piedracoba C, Castellano-Tortajada G. Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol 2015;8:257-69. [PMID: 26316792 DOI: 10.2147/CEG.S58152] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
184 Biancheri P, Brezski RJ, Di Sabatino A, Greenplate AR, Soring KL, Corazza GR, Kok KB, Rovedatti L, Vossenkämper A, Ahmad N, Snoek SA, Vermeire S, Rutgeerts P, Jordan RE, MacDonald TT. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Gastroenterology 2015;149:1564-1574.e3. [PMID: 26170138 DOI: 10.1053/j.gastro.2015.07.002] [Cited by in Crossref: 68] [Cited by in F6Publishing: 75] [Article Influence: 9.7] [Reference Citation Analysis]
185 Seo GS, Chae SC. Biological therapy for ulcerative colitis: An update. World J Gastroenterol. 2014;20:13234-13238. [PMID: 25309060 DOI: 10.3748/wjg.v20.i37] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
186 Gisbert JP, Marín AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 2015;42:391-405. [PMID: 26075832 DOI: 10.1111/apt.13276] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 10.0] [Reference Citation Analysis]
187 Geng S, Chang H, Qin W, Lv M, Li Y, Feng J, Shen B. A novel anti-TNF scFv constructed with human antibody frameworks and antagonistic peptides. Immunol Res 2015;62:377-85. [PMID: 26059602 DOI: 10.1007/s12026-015-8667-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
188 Quetglas EG, Armuzzi A, Wigge S, Fiorino G, Barnscheid L, Froelich M, Danese S. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol 2015;71:773-99. [PMID: 26008212 DOI: 10.1007/s00228-015-1862-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
189 Jiang W, Li X. Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy. Mol Diagn Ther 2015;19:141-58. [DOI: 10.1007/s40291-015-0142-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
190 Billiet T, Ferrante M, Van Assche G. The use of prognostic factors in inflammatory bowel diseases. Curr Gastroenterol Rep. 2014;16:416. [PMID: 25262067 DOI: 10.1007/s11894-014-0416-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
191 Nguyen DL, Flores S, Sassi K, Bechtold ML, Nguyen ET, Parekh NK. Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease. Ther Adv Chronic Dis 2015;6:147-54. [PMID: 25954499 DOI: 10.1177/2040622315579621] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
192 Papamichael K, Vermeire S. Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease. World J Gastroenterol 2015; 21(16): 4773-4778 [PMID: 25944990 DOI: 10.3748/wjg.v21.i16.4773] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
193 Dirisala VR, Jeevan A, Ly LH, McMurray DN. Molecular and biochemical characterization of recombinant guinea pig tumor necrosis factor-alpha. Mediators Inflamm 2015;2015:619480. [PMID: 25999670 DOI: 10.1155/2015/619480] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
194 Ananthakrishnan AN, Kane SV. The Toronto consensus guidelines for nonhospitalized ulcerative colitis: a welcome update but not the end of the story. Gastroenterology 2015;148:877-80. [PMID: 25805424 DOI: 10.1053/j.gastro.2015.03.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
195 Chaturvedi D, Dwivedi PK, Chaturvedi AK, Mishra N, Siddiqui HH, Mishra V. Semisynthetic hybrids of boswellic acids: a novel class of potential anti-inflammatory and anti-arthritic agents. Med Chem Res 2015;24:2799-812. [DOI: 10.1007/s00044-015-1331-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
196 Marie I, Leroi AM, Menard JF, Levesque H, Quillard M, Ducrotte P. Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev 2015;14:547-54. [PMID: 25661980 DOI: 10.1016/j.autrev.2015.01.018] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
197 Guerra GC, Araújo AA, Lira GA, Melo MN, Souto KK, Fernandes D, Silva AL, Araújo Júnior RF. Telmisartan decreases inflammation by modulating TNF-α, IL-10, and RANK/RANKL in a rat model of ulcerative colitis. Pharmacol Rep 2015;67:520-6. [PMID: 25933964 DOI: 10.1016/j.pharep.2014.12.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
198 Dubé PE, Punit S, Polk DB. Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2015;308:G161-70. [PMID: 25477373 DOI: 10.1152/ajpgi.00142.2014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
199 Bonneau J, Dumestre-Perard C, Rinaudo-Gaujous M, Genin C, Sparrow M, Roblin X, Paul S. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes. Autoimmun Rev. 2015;14:231-245. [PMID: 25462578 DOI: 10.1016/j.autrev.2014.11.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
200 Ma HD, Wang YH, Chang C, Gershwin ME, Lian ZX. The intestinal microbiota and microenvironment in liver. Autoimmun Rev. 2015;14:183-191. [PMID: 25315744 DOI: 10.1016/j.autrev.2014.10.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
201 Beniwal-Patel P, Saha S. The role of integrin antagonists in the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2014;14:1815-23. [PMID: 25288228 DOI: 10.1517/14712598.2014.967209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
202 Seo GS, Chae SC. Biological therapy for ulcerative colitis: An update. World J Gastroenterol 2014; 20(37): 13234-13238 [PMID: 25309060 DOI: 10.3748/wjg.v20.i37.13234] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
203 Lin K, Mahadevan U. Pharmacokinetics of Biologics and the Role of Therapeutic Monitoring. Gastroenterology Clinics of North America 2014;43:565-79. [DOI: 10.1016/j.gtc.2014.05.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
204 Vavricka SR, Radivojevic S, Manser CN, Frei P, Burri E, Fried M, Schoepfer A, Peyrin-Biroulet L, Michetti P, Rogler G, Biedermann L. Addressing current treatment challenges in Crohn's disease in real life: a physician's survey. Dig Liver Dis 2014;46:1066-71. [PMID: 25169961 DOI: 10.1016/j.dld.2014.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
205 Kopylov U, Al-Taweel T, Yaghoobi M, Nauche B, Bitton A, Lakatos PL, Ben-Horin S, Afif W, Seidman EG. Adalimumab monotherapy vs combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8:1632-1641. [PMID: 25067824 DOI: 10.1016/j.crohns.2014.07.003] [Cited by in Crossref: 61] [Cited by in F6Publishing: 66] [Article Influence: 7.6] [Reference Citation Analysis]
206 Ho TY, Lo HY, Chao DC, Li CC, Liu JJ, Lin C, Hsiang CY. Electroacupuncture improves trinitrobenzene sulfonic Acid-induced colitis, evaluated by transcriptomic study. Evid Based Complement Alternat Med 2014;2014:942196. [PMID: 24995035 DOI: 10.1155/2014/942196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
207 Mendes de Abreu M, Strand V, Levy RA, Araujo DV. Putting the value into biosimilar decision making. Autoimmunity Reviews 2014;13:678-84. [DOI: 10.1016/j.autrev.2014.01.051] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
208 de Boer NKh, Löwenberg M, Hoentjen F. Management of Crohn's disease in poor responders to adalimumab. Clin Exp Gastroenterol 2014;7:83-92. [PMID: 24748811 DOI: 10.2147/CEG.S47627] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
209 Olivieri I, Cantini F, Castiglione F, Felice C, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Vecchi M, Armuzzi A. Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev. 2014;13:822-830. [PMID: 24726868 DOI: 10.1016/j.autrev.2014.04.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 6.9] [Reference Citation Analysis]
210 Chang C. Unmet needs in the treatment of autoimmunity: from aspirin to stem cells. Autoimmun Rev 2014;13:331-46. [PMID: 24462645 DOI: 10.1016/j.autrev.2014.01.052] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
211 Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014;11:243-55. [PMID: 24393836 DOI: 10.1038/nrgastro.2013.253] [Cited by in Crossref: 128] [Cited by in F6Publishing: 120] [Article Influence: 16.0] [Reference Citation Analysis]
212 Cassinotti A, Sarzi-puttini P, Fichera M, Shoenfeld Y, de Franchis R, Ardizzone S. Immunity, autoimmunity and inflammatory bowel disease. Autoimmunity Reviews 2014;13:1-2. [DOI: 10.1016/j.autrev.2013.06.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
213 Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev 2014;13:54-8. [PMID: 24035809 DOI: 10.1016/j.autrev.2013.09.002] [Cited by in Crossref: 104] [Cited by in F6Publishing: 106] [Article Influence: 11.6] [Reference Citation Analysis]